Stock Market & Financial Investment News

News Breaks January 10, 2013 13:05 EDT TSPT, SNY FDA doesn't require labeling changes for Intermezzo in review of sleep aids The FDA announced earlier that it is requiring Sanofi (SNY), the manufacturer of Ambien, and some makers of other insomnia drugs that contain zolpidem, to lower the recommended dose. The FDA said the recommended bedtime dose should be lowered because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving. The FDA said recommended doses of Transcept Pharmaceuticals' (TSPT) Intermezzo, a lower dose zolpidem product approved for middle-of-the-night awakenings, are not changing. At the time of Intermezzo’s approval in November 2011, the label already recommended a lower dosage for women than for men, the FDA noted. In afternoon trading, shares of Transcept rose 16c, or 3.04%, to $5.43. Reference Link News For TSPT;SNY From The Last 14 Days Check below for free stories on TSPT;SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 08:03 EDT SNY Sanofi reports positive topline results from pivotal Phase III Jakarta study Subscribe for More Information 05:18 EDT SNY Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint Subscribe for More Information May 15, 2013 15:16 EDT SNY Sanofi systemic sclerosis treatment designated for orphan drug status Subscribe for More Information 05:39 EDT SNY Sanofi, Regeneron announce patient enrollment in two Phase 3 trials Subscribe for More Information May 13, 2013 17:12 EDT TSPT Transcept Pharmaceuticals partner to stop using Intermezzo sales reps Subscribe for More Information 09:44 EDT SNY Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information 07:30 EDT SNY TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. May 10, 2013 11:48 EDT SNY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 07:25 EDT TSPT Transcept Pharmaceuticals downgraded to Hold from Buy at MLV Equity May 9, 2013 08:00 EDT TSPT Transcept downgraded to Market Perform from Outperform at JMP Securities JMP securities downgraded Transcept following weak script data for Intermezzo. 05:36 EDT TSPT Transcept downgraded to Market Perform from Outperform at Leerink Leerink downgraded Transcept Pharmaceuticals citing weak script data for Intermezzo and lowered its price target range for shares to $4-$5 from $7-$8. May 8, 2013 13:27 EDT TSPT Transcept Pharmaceuticals reports Q1 EPS (56c), consensus (36c) Transcept reported cash, cash equivalents and marketable securities of $81.1M at March 31. May 6, 2013 07:49 EDT SNY Bernstein's global pharmaceuticals analyst has analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.